36 Results

People

  1. Intlekofer
    Intlekofer
  2. Levine
    Levine
  3. Younes
    Younes
  4. Zelenetz
    Zelenetz
  5. Dogan
    Dogan
  6. Palomba
    Palomba
  7. Van Den Brink
    Van Den Brink
  8. Abdel-Wahab
    Abdel-Wahab
  9. Batlevi
    Batlevi
  10. Moskowitz
    Moskowitz

Groups

  1. Center for Hematologic Malignancies (36)
  2. Department of Medicine (36)
  3. Executive Committee, Center for Hematologic Malignancies (36)
  4. GSK Faculty (36)
  5. Hematologic Malignancies Research (36)
  6. Hematologic Malignancies, Division of (36)
  7. Human Oncology and Pathogenesis Program (36)
  8. Lymphoma (36)
  9. Adult Leukemia (22)
  10. Sloan Kettering Institute Faculty (20)
  1. "Hematologic Malignancies Research"
  2. "Executive Committee, Center for Hematologic Malignancies"
  3. "Andrew Intlekofer"
Formats
  1. Meeting Abstract (24)
  2. Journal Article (12)
Groups
  1. Center for Hematologic Malignancies (36)
  2. Department of Medicine (36)
  3. Executive Committee, Center for Hematologic Malignancies (36)
  4. GSK Faculty (36)
  5. Hematologic Malignancies Research (36)
  6. Hematologic Malignancies, Division of (36)

More Groups

People
  1. Andrew Intlekofer (36)
  2. Ross Levine (22)
  3. Anas Younes (18)
  4. Ahmet Dogan (15)
  5. Andrew Zelenetz (15)
  6. Maria Palomba (14)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2019 (3)
  4. 2018 (4)
  5. 2017 (7)
  6. 2016 (3)

More Years

Publications
  1. Blood (19)
  2. Cancer Discovery (3)
  3. Laboratory Investigation (2)
  4. Modern Pathology (2)
  5. Nature (2)
  6. Blood Cancer Journal (1)

More Publications

Publishers
  1. American Society of Hematology (19)
  2. Nature Publishing Group (6)
  3. American Association for Cancer Research (4)
  4. Nature Research (2)
  5. American Society for Clinical Investigation (1)
  6. Cold Spring Harbor Laboratory Press (1)

More Publishers

Results (36)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations
    Meeting Abstract

    Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Schade, J. R.; Kim, C.; Drill, E.; Qiu, A.; Batlevi, C. L.; Caron, P.; Colbourn, D. S.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis
    Journal Article

    Yoshimi, A.; Lin, K. T.; Wiseman, D. H.; Rahman, M. A.; Pastore, A.; Wang, B.; Lee, S. C. W.; Micol, J. B.; Zhang, X. J.; de Botton, S.; more...
    Nature (2019)

    Fulltext@MSK | Save
  • Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition
    Journal Article

    Harding, J. J.; Lowery, M. A.; Shih, A. H.; Schvartzman, J. M.; Hou, S.; Famulare, C.; Patel, M.; Roshal, M.; Do, R. K.; Zehir, A.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
    Journal Article

    Intlekofer, A. M.; Shih, A. H.; Wang, B.; Nazir, A.; Rustenburg, A. S.; Albanese, S. K.; Patel, M.; Famulare, C.; Correa, F. M.; Takemoto, N.; more...
    Nature (2018)

    Fulltext@MSK | Save
  • Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay
    Journal Article

    Intlekofer, A. M.; Joffe, E.; Batlevi, C. L.; Hilden, P.; He, J.; Seshan, V. E.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, C. H.; Portlock, C.; more...
    Blood Cancer Journal (2018)

    Fulltext@MSK | Save
  • JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
    Journal Article

    McKenney, A. S.; Lau, A. N.; Hanasoge Somasundara, A. V.; Spitzer, B.; Intlekofer, A. M.; Ahn, J.; Shank, K.; Rapaport, F. T.; Patel, M. A.; Papalexi, E.; more...
    Journal of Clinical Investigation (2018)

    Fulltext@MSK | Save
  • Spliceosomal dysfunction Is a critical mediator of IDH2 mutant leukemogenesis
    Meeting Abstract

    Yoshimi, A.; Lin, K. T.; Wiseman, D.; Intlekofer, A. M.; Wang, B.; Pastore, A.; Rahman, M.; Lee, S. C. W.; Liu, B.; Micol, J. B.; more...
    Blood (2017)

    Fulltext@MSK | Save